NOVATO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Shalini Sharp, Chief Financial Officer, will be presenting at the Stifel Nicolaus Weisel Healthcare Conference 2012 in Boston, MA on September 6 at 10:20am Eastern Time. The conference is being held at the Four Seasons Hotel, 200 Boylston Street, Boston, MA.
About Ultragenyx
Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan and ultra-orphan diseases, to market. The company focuses on rare metabolic diseases that affect small numbers of patients, but for which the unmet medical need is high and there are no effective treatments. Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these underserved diseases.
The company is led by an experienced management team in rare disease therapeutics. Ultragenyx is striving toward an improved model for successful rare disease drug development, which has the potential to increase efficiency while maintaining appropriate safety and efficacy standards. The company believes that it can deliver significant value to patients by building a high-quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine.
For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.